Clay Siegall, Ph.D.

Clay Siegall, Ph.D.

President, Chief Executive Officer and Chairman of the BoardatImmunome· In proxies 2023–2025

Pay in FY2024-38% from the year before · Immunome stock -0.7% the same year

Clay Siegall, Ph.D. was paid $9.2M in FY2024 (Dec), down 38%. Immunome stock fell 0.7% that year.

Pay$100 in the stock at the end of FY22 → $481
Pay is from the Summary Compensation Table of each Immunome proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ImmunomePublic company · 3 yr
    • President, Chief Executive Officer and Chairman of the Board2023 – Present · 3 yrStock in role +575%
  2. Shattuck Labs, Inc.Public company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  3. Alder BioPharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Mirna Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Nurix Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Ultragenyx Pharmaceutical Inc.Public company
    • Director? – PresentNo stock prices for these years
  7. Umoja Biopharma, IncPublic company
    • Director? – PresentNo stock prices for these years
  8. Tourmaline Bio, Inc.Public company · 2 yr
    • Director2023 – 2025 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?